American Healthcare REIT, Inc. (NYSE:AHR) is one of the On May 28, 2026, KeyBanc raised the firm’s price target on American Healthcare REIT, Inc. (NYSE:AHR) to $58 from $55 and maintained an Overweight rating on the shares.
KeyBanc said American Healthcare REIT remains well-positioned to benefit from strength across its RIDEA segments and a fortified balance sheet following last week’s equity issuance
The firm also raised its 2026 NFFO estimate by about 5% to $2.11 per share and its 2027 NFFO estimate by 6% to $2.40 per share, citing upside to the company’s 2026 SSNOI growth outlook, earnings accretion from awarded acquisitions, and a robust investment pipeline. On May 26, 2026, RBC Capital analyst Michael Carroll raised the firm’s price target on American Healthcare REIT, Inc. (NYSE:AHR) to $56 from $54 and maintained an Outperform rating on the shares. Carroll said the company delivered a solid earnings report, highlighted by healthy organic growth and an attractive investment pace.
Earlier in May, American Healthcare REIT, Inc. (NYSE:AHR) reported Q1 normalized FFO of 50c, ahead of the consensus estimate of 47c. Revenue totaled $650.77M, below the consensus estimate of $687.04M. CEO Jeff Hanson said the quarter reflected an “exceptionally strong period” across core metrics, including the company’s ninth consecutive quarter of double-digit Same-Store NOI growth, efficient capital formation and deployment, a strengthened balance sheet, and a raise to full-year 2026 Same-Store NOI growth and NFFO per share guidance.